REKOVELLE (Follitropin Delta)

DRUG2 trials

Sponsors

Ferring Pharmaceuticals, Centre Hospitalier Intercommunal Creteil

Conditions

InfertilityInsemination

Phase 2

Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)

RecruitingNCT07153367

Centre Hospitalier Intercommunal CreteilInfertility, Insemination

Start: 2025-12-17End: 2028-03-17Target: 80Updated: 2026-04-08

Phase 3

A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation

CompletedNCT05263388

Ferring PharmaceuticalsInfertility

Start: 2022-07-15End: 2024-04-16Updated: 2025-04-02

Related Papers

Ovarian stimulation with follitropin delta for <i>in vitro</i> fertilization: a multicentre, randomized, assessor-blind comparison with follitropin alfa using conventional dosing regimens (ADAPT-1 trial)

Human Reproduction2025-06-12